Amgen Inc. is experiencing renewed investor interest despite a recent 0.4% decline in stock price, as Wall Street grows optimistic about the company's profitability stemming from new pharmaceutical deals with the White House. Analysts view Amgen as a strong investment due to its robust operating margin of 24.1% and anticipated annual sales growth of 15.8%, coupled with ongoing developments like the investigational obesity drug MariTide. The company is also expanding its rare disease portfolio through the acquisition of Horizon Therapeutics, positioning itself favorably in a recovering biotech sector.
“One other stock in the same industry, Amgen (AMGN), finished the last trading session 0.4% lower at $327.31.”
“While those worries previously kept investors at bay, Wall Street appears to be increasingly warming up to the idea that recent big pharma deals with the White House will allow the industry to sidestep a broader, profit-margin-busting reckoning. The performance of major drugmakers has been solid, and not just the GLP-1 weight loss Giant Eli Lilly (LLY), which had already made a significant move due to surging demand.”
“For now, interest in healthcare stocks is due mainly to: Portfolio rebalancing to normalize weights. Diversification to play some defense after a big multiyear rally. Growing optimism that regulatory risks are overblown. Rising merger & acquisition opportunity.”
“Amgen · boasts one of the largest portfolios in the biotech industry · oncology, cardiovascular disease, inflammation, bone health and rare diseases”
“Amgen · is evaluating · Repatha, Uplizna, Tepezza and Tavneos for additional indications”
“BMY · has fetched slightly better returns than · AMGN in the past six months”
“AMGN · currently trades at · 15.2X forward earnings”
“BMY · has a dividend yield of · 4.54% · higher than AMGN’s 2.86%”
“AMGN · is a better pick at present · despite its pricey valuation”
“Amgen · has · Trailing 12-Month GAAP Operating Margin · 24.1%”
“Amgen · has a · late-stage obesity candidate · true”
“Amgen · is developing · MariTide · true”
